India, Feb. 9 -- Biotech startup Pandorum Technologies has bagged $18 Mn (INR 163 Cr) in a Series B funding round led by Protons Corporate, with participation from Galentic Pharma, Noblevast Advisory and Avinya Fund, Burman Family, alongside existing investor Ashish Kacholia, among others.

The fresh capital will be deployed to advance the Bengaluru-based startup's bid to develop disease-modifying, tunable, exosome-based therapies, including Kuragenx. A portion of the capital will also be allocated to scale its global manufacturing and expand operations across the US, Japan, and the Middle East.

"This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue app...